Reviva Pharmaceuticals Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Brilaroxazine showed robust, durable efficacy and a favorable safety profile in phase III trials for schizophrenia, outperforming historical antipsychotics and addressing key unmet needs. A second phase III trial is planned, with NDA submission targeted for 2028 and potential exclusivity to 2046.
-
Brilaroxazine showed robust, sustained efficacy and safety in phase III schizophrenia trials, with minimal relapse and superior differentiation versus current antipsychotics. A second confirmatory trial is planned, with NDA filing targeted for early 2028 and potential patent exclusivity to 2046.
-
Brilaroxazine is advancing to a pivotal phase III trial for schizophrenia, with a new formulation designed to extend patent life to 2046. Pending FDA feedback, the company aims to expand indications and regain Nasdaq compliance, supported by a strong financial position and major upcoming catalysts.
-
Brilaroxazine is advancing to a second phase III trial in schizophrenia, with a new formulation aimed at extending patent life to 2046. FDA feedback on the formulation switch is expected mid-year, and the trial is set to start in Q3, leveraging strong prior data and a solid financial runway.
Fiscal Year 2025
-
Brilaroxazine, in phase III for schizophrenia, showed robust efficacy for both primary and negative symptoms, superior adherence, and a favorable safety profile. Full data is expected in Q2 2025, with NDA submission targeted for end of 2026.
Fiscal Year 2024
-
Brilaroxazine showed rapid, robust efficacy in phase III schizophrenia trials, outperforming established antipsychotics on key endpoints and demonstrating strong safety and adherence. Novel vocal biomarker analysis validated clinical outcomes and is being integrated into ongoing studies, with regulatory interest supporting future adoption.